initi outperform pt
come back life
initi coverag ew share outperform rate
pt upsid ew share under-perform med-tech
peer group ytd investor worri competit threat
specif potenti growth slowdown
see key debat shape ew stori
competit think fear overdon think
entri us delay late proprietari
survey show major tavr doc expect pma submiss
push time risk trial result could
catalyst ew
tavr growth outlook intact survey show tavr grow high
teen rate suggest ew guid could
conserv provid room upsid surpris
final ew one robust pipelin med-tech st
assign minim valu manag recent asr signal
optim around histor ew return post asr suggest
share current level buy opportun
valuat price target base dcf methodolog
contempl wacc termin ebitda multipl
equat perpetu growth rate price-to-earnings basi
translat premium vs line year
averag vs year averag year
downsid risk sooner expect entri boston
scientif us market accentu price pressur
impact growth margin potenti neg headlin
relat program mitral tavr
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
come back life
last page report import disclosur regard stock report
floydian grind initi
tabl content
debat impact bsx us tavr launch lack thereof
debat sustain tavr market growth ir impact
debat time investor give credit pipelin
iv thesi risk
leader tavr fastest grow market msd
dd organ top-line mainli driven tavr growth
ceo mike mussallem year experi
medic devic includ year ew
cfo scott ullem year experi includ
year invest bank
transcathet valv tavr repres
sale growth driver
mix shift tavr improv margin
yr strength ew share u/p
margin
corpor gross margin
investor fear competit
weigh recent share perform
investor debat head
potenti impact lack thereof boston
scientif entri us tavr market
intermedi risk sustain growth pipelin
investor give credit ew pipelin
pipelin worth
debat competit bsx potenti us entri
saw hsd share mo post lotu launch eu
result deceler ew ou growth
lotu launch
retreat low
similar share gain us could hit ew growth
delay pma submiss give ew window
impact ew us
assum boston scientif share gain half stem edward
pma submiss specif unknown
experienc valid challeng product
test result continu issu
updat come earn call
question bsx second delay chang
dynam potenti share shift favor ew
debat evrisi tavr survey gaug physician view
tavr implant mix amongst respond vendor
given extraordinari amount investor fear
competit share loss decid conduct tavr
survey gaug physician attitud
survey conduct decemb physician
time digest bsx announc regard lotu
respond non-profit
profit
chart evercor isi transcathet aortic valv tavr survey
debat potenti lotu delay lower risk ew
major survey respond think lotu fda pma file could move month delay
question think resolv deliveri issu lotu valv expect file pma fda
dont know view
unpredict deliveri issu make hard resolv
ye fda time push
ye solv issu expect fda pma file delay
ye solv issu expect fda pma file delay
ye solv issu submit fda pma
respond think pma file
either delay
abl resolv issu
respond
initi physician reaction delay seem take cautiou approach understand ew
question latest
announc delay lotu chang view
usabl lotu edg tavr
concern
use lotu
launch
ye make
cautiou usag
would depend earli
experi first
ye concern
use
lotu valv
ye concern
use lower
amount lotu valv
vs prior
debat small impact lr could off-set
respond expect lotu gain share mon ew us
question expect
lotu tavr devic gain share launch
us
think equat bp impact ew tavr growth assum launch end
loss
could switch
share loss ew
hit
could small impact ew risk data could reacceler
market growth like off-set
debat size ir oppti also debat
bear point declin st score impli ir pt treat growth like slow
averag st score
tvt registri
steadili declin
societi thorac surgeon st score use
stratifi tavr patient risk
intermedi risk ir st score
tvt registri average st impli ir
patient treat therebi impli
increment ir lower st expec
patient
score
patient
american colleg cardiolog present tvt registri
ew believ tavr expand market
tvt registri support ew view expans
evidenc age distribut tavr
savr patient tavr patient older
averag age tavr patient treat still
impli previous untreat patient come
sidelin make st debat irrelev
factor play role older patient
american colleg cardiolog present tvt registri
debat street fear drastic slowdown tavr growth
given bear view size ir market compound competit fear
ew rel multipl discount growth asset impli st fear meaning
slowdown growth
recent analyst day dec ew guid overal tavr growth
rang in-lin market
given tavr growth guid
surfac seem play bear thesi
question investor tavr market go deceler meaning
could growth rate look like ew guidanc conserv
question expect tavr implant volum growth versu
question expect tavr implant volum growth versu
 compar growth estimate
tavr growth vs
tavr growth vs
saniti check respond answer tavr volum expect ask expect volum
growth get baselin respons rate
respond expect implant volum grow compar ew potenti us growth rate
growth hint respons close trend seen market
tavr survey show growth remain healthi mid high teen
debat credit pipelin jekyl hyde
launch
eu introduct expect year end
implant resum
ew could potenti expand street seem give zero
credit robust pipelin unlik curiou case jekyl hyde
debat survey show bar lr reason
major physician think tavr need show equival savr doc start use tavr risk pt
question clinic standpoint bar tavr need achiev vs savr surgic valv use low risk patient
term
risk recal trial low risk sever symptomat aortic stenosi patient design non inferior
trial rel non inferior margin trial result like read
bar lr seem reason especi given excel result sub group studi
patient st expect lr meaning growth driver
debat doc bullish asymptomat moder
healthi respond seem posit tavr penetr asymptomat hr moder risk patient
question think tavr therapi moder
becom standard care futur
question think tavr therapi asymptomat sever
aortic stenosi patient earli tavr becom
standard care futur
need wait see data play earli physician interest
potenti larg opportun seem posit contrast street
mgmt histori asr time make set-up interest
management histor time asr sharehold fear high compani specif catalyst event
recent analyst day dec manag announc mm asr also note repurchas anoth
mm earli open market transact total mm repurchas
ew done mm asr past year coincid period either investor nervous
peak specif catalyst around corner
asr announc mm asr februari ahead ir pivot trial data present apr
ew us tavr growth acceler grew
asr announc mm asr august investor worri mdt entri us
ew award preliminari injunct mdt sale corevalv apr subsequ settl
may post us tavr growth acceler
seen figur stock return post histor asr suggest asr catalyt event ew
qoq decel
fear weigh stock
believ current asr repres buy opportun investor
invest thesi valuat framework
dcf pt equat tgr rang
ebita margin vs current ebita margin
discount ebitda termin free flow enterpris total valu valu per ew perpetu growth valu enterpris enterpris valu januari
evercor isi vs consensu valuat framework
street sale
street ep
dcf pt equat price-to-earnings base in-lin histor prem vs
pt equat price-to-earnings premium
year averag
invest thesi risk
ew share compel given premium growth profil initi outperform rate pt
believ competit fear overdon especi given second delay pma file believ
minim impact contrast market sentiment
major physician proprietari survey expect pma file push would put
potenti launch late time-frame
addit believ tavr market growth outlook remain intact physician survey expect high teen
growth vs given view think ew set rais stori
ew one robust pipelin program med-tech could potenti expand
believ market assign minim valu current level contrast favor physician view
survey show bar risk potenti launch achiev physician remain posit
moder asymptomat opportun
final ew histor time asr either investor fear high ahead potenti catalyst think
recent asr dec signal buy opportun given histor stock return post asr announc
sooner expect entri boston scientif us market result growth deceler edward
accentu price pressur impact growth margin
potenti neg headlin relat program risk earli tavr unload trial mitral program
note yield price-to-earnings multipl base current stock price evrisi estim
million except per share data fy end decemb organ gp less op less ep share inc net inc price-to-earnings prem disc januari
thank luck
medic suppli devic
healthcar facil manag
valuat methodolog base mix discount cash flow analysi rel valuat multipl
risk valuat includ regulatori risk overal market risk well unforeseen event relat individu cover
compani broader sector includ new competit product technolog
articl articl
time dissemin januari et
analyst vijay kumar brittani henderson primarili respons prepar research report attest follow
view opinion render research report reflect person view subject compani issuer
part research analyst compens directli relat specif recommend view research report
